Hepatitis C New Drug Research And Liver Health
  • HCV News Of The Day
    • 2013/HCV Drugs News Digest
    • HCV Drugs: News Digest>
      • News Archive
      • Liver HCV : Specialty news digest
  • 2013 - Breaking Conference Reports/Hepatitis C
    • Breaking Conference Reports >
      • EASL 2012 Meeting Summary>
        • EASL Summary Of The 2011 March Meeting
      • AASLD- Nov 2011 Annual Meeting>
        • Conference Archive
  • Blog: New HCV Drug Updates
  • HCV FAQ
  • HCV: Newly Diagnosed?
    • Challenges-issues in managing hepatitis C
    • Ask Me A Question About Hepatitis C
  • What to do with a positive hepatitis C test
  • 2013-HCV Abstract Corner
    • HCV Abstract Corner>
      • Archive; Abstract Corner
  • 2013-Hepatitis C Full Text Articles
    • Hepatitis C Treatment Complete Studies 2012>
      • Potential new method to block the lifecycle of the Hepatitis C virus
      • Hepatitis C Treatment Complete Studies 2011
  • 2013/HCV Multimedia Videos Podcasts
    • Multimedia/Videos-Podcasts>
      • Watch How Hepatitis C Protease Inhibitors Work>
        • Multimedia; Archives Videos and Podcasts
  • 2013 Stem Cell News and Research
    • Liver-2012 Stem Cell Updates
    • Liver: 2011 Stem Cell Updates
    • What Are Stem Cells?>
      • Future applications of human stem cells
  • Recommended; Stem Cell Blogs
  • Understanding Hepatitis C
  • Natural History Of HCV
    • A 20-year cohort study on the natural history of untreated HCV infection
  • Hepatitis C Disease Progression
    • NIH scientists identify likely predictors of hepatitis C severity
    • HCV Epidemiology, Diagnosis and Disease Progression
    • Hepatitis C may increase deaths from both liver-related and other diseases>
      • Mortality in advanced HCV /long-term peginterferon
    • Host Factors on Management of HCV
  • Transmission
    • How Soon To Initiate HCV Therapy After Transmission
    • Does the Hepatitis C virus survive in dried blood ?
    • Viral Load Tied to Vertical Transmission of Hepatitis C
    • Hey Can I Get Hep C From......
    • HCV infections transmitted via a clinical setting
    • What Should I Do If I Get A Needlestick
  • How are the different types of hepatitis transmitted
    • New challenges in viral hepatitis
    • Hepatitis A virus infection in high-risk subjects
  • Your Liver Functions
  • Liver Function Tests
    • HCV-Persistently Normal (ALT) Alanine Aminotransferase Levels
    • Hey, I have a question about hcv tests and my liver
    • ALT used to separate those infected with HCV from those at low risk of liver disease
  • Lab Reports
  • HCV Viral Load Test
  • Liver Biopsy/Noninvasive Tests
    • Is there still a role for liver biopsy in managing hepatitis C virus infections?
    • Overview of Liver Biopsy Procedure
    • Three Algorithms of Non-invasive Markers of Fibrosis in Chronic Hepatitis C
    • FibroScan comparison to liver fibrosis biomarkers
  • Chronic HCV Symptoms
    • Fatigue and HCV
    • Sleep Disturbance in Chronic HCV
    • Skin Rash/Hepatitis C
    • Liver Disease: Bone Loss "It Ain't Like Menopause!"
  • HCV Neuropsychiatric symptoms-“brain fog”
    • HCV-Related Nervous System Disorders
    • Hepatitis C Virus and the Brain
    • Liver-induced inflammation hurts the brain
    • The Brain on Fire: Inflammation and Depression
  • Conditions Outside The Liver
    • Prevalence of fibromyalgia among patients with chronic hepatitis C
    • Lichen Planus and The Hepatitis C Virus
    • Dermatologic Disorders and Liver Disease
  • Chronic hepatitis C: Treat or wait?
    • Preparing For Treatment>
      • Starting Hepatitis C Treatment: Tips and Information 2011
      • Adherence To HCV Treatment-Review
      • Treating Hepatitis C; What can you do to increase your chance for SVR?
  • Hepatitis C advanced fibrosis: Treat or Wait
  • Approved Treatments for Hepatitis C
    • Adults:Treating Hepatitis C
    • Interferons and hepatitis C virus
  • HCV Treatment Failure Can Still Mean Less Liver Inflammation
  • Protease inhibitors geno-1:New standard of care
    • Treating HCV Genotype 1 In The Real World
    • 2012 - Direct acting antivirals for the treatment of chronic hepatitis C
    • HCV:End of the Beginning-Possibly-Beginning of the End
    • Patients’ Expectations About New HCV Direct-Acting Antivirals Often Unrealistic
    • What Are NS5A inhibitors ?
    • Hepatitis C Treatment Nonresponders
    • New 2011 AASLD guidelines for treating HCV
    • Treating New and Old Therapies>
      • High-grade liver inflammation may predict treatment response
  • HCV Resistance To New And Experimental Drugs
    • Understanding Resistance in Chronic HCV Infection
  • 2012 Future Prospects-Treatment of HCV
    • Advances in the treatment of hepatitis C virus infection.
  • Boceprevir & Telaprevir
    • FDA Telaprevir/Boceprevir Transcript
    • Pocket Guide Telaprevir/Boceprevir
    • Quick Facts- Direct-acting antivirals Telaprevir/Boceprevir
    • Telaprevir Or Boceprevir: What Is My Chance For A Cure?
  • 2013 News/Incivek (Telaprevir)
    • News/Telaprevir>
      • Telaprevir-IFN/ribavirin Hints at Response
      • Telaprevir FDA Approval>
        • Help-How Do I Take Incivek-telaprevir ?
        • Quick Study Of Telaprevir
        • Cost Of Treating With Telaprevir
  • 2013 News/Victrelis (Boceprevir)
    • News/ Boceprevir>
      • VICTRELIS-Boceprevir: Prescribing-Medication Guide
      • 2011;Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection
      • 2011-Boceprevir for Untreated Chronic HCV Genotype 1 Infection
  • Side Effects-Interferon Free Therapies
  • Drug-Drug Interactions In Triple-Therapy
  • 2013/HCV Triple-therapy Side Effects
    • Boceprevir,Telaprevir Less Side Effects?>
      • 2013-HCV therapy geno 1: management of side-effects
      • Dry Mouth and Treatment >
        • Dry Mouth (Xerostomia)
      • Important updates to PegIntron labeling
      • Peginterferon alfa-2a Drug Interactions
      • HCV Treatment: Peginterferon and Ribavirin Side Effects
  • Genotypes/Treatment
    • Treatment Duration in Hepatitis C Virus Genotype 2/3-infected Patients
    • Impact of IL28B on Liver Histopathology in HCV Genotype 2/3
    • Genotype 3/HCV Treatment
    • HCV-Genotype 5 or 6
    • Hepatitis C-Genotype 4>
      • How to optimize HCV therapy in genotype 4 patients
      • Geno 4-Pioglitazone Decreases HCV Viral Load
    • Telaprevir/Boceprevir *genotype 1,2,3
    • (HCV) genotypes in the severity of liver disease
  • What Is The IL28B gene ?
    • Hepatitis C Test:Likelihood of achieving SVR>
      • IL28B and HCV immune responses
  • Index-Current Hepatitis C Drugs In Development
  • 2013-Interferon Free Combinations
    • Interferon-free combinations
    • 2013-Interferon free therapy w-direct acting antivirals for HCV
  • 2013 Sofosbuvir (GS-7977)
    • GS-7977-Formally PSI-7977 >
      • PSI-7977 peg/riba Geno 2/3 PROTON Trial
  • Sofosbuvir(GS7977)/Simeprevir(TMC435)
    • Interferon-Free Combo PSI-7977-TMC435
  • Sofosbuvir (GS-7977)/Ledipasvir (GS-5885)
  • GS-5885, an NS5A Inhibitor
  • ABT-450/r, ABT-267, ABT-333
  • Faldaprevir (BI 201335) and BI 207127 Interferon-Free
    • NS3/4A protease inhibitor BI201335
  • Miravirsen First MicroRNA-Targeted Drug
  • BMS-790052 (Daclatasvir)
  • Daclatasvir/VX135
  • ALS-2200 (VX-135)
  • BMS-790052/BMS-650032 Interferon-sparing
  • (TMC435) Simeprevir
  • TMC435 monotherapy in HCV genotypes 2-6
  • Simeprevir (TMC435) and TMC647055
  • Simeprevir,TMC647055 and IDX719
  • TMC435-daclatasvir-BMS-790052
  • Danoprevir-RG7227 direct-acting antiviral
  • Mericitabine- Polymerase Nuc
  • Sovaprevir (Formerly ACH-1625)
  • ACH-3102 NS5A inhibitor
  • INCIVEK, VX-222/Ribavirin
  • MK-5172 protease inhibitor
  • HCV/New Drug Pipeline
  • 2013/Hepatitis C Clinical Trials
    • Clinical Trials>
      • Learning About Clinical Trials
      • Boceprevir and Telaprevir Trials>
        • Telaprevir REALIZE STUDY
  • HCV Trials/Discontinued Or On Hold
    • Idenix IDX184-Hepatitis C drug
    • TMC435-BMS-986094-formerly INX-189
  • Women's Health; Treating Hepatitis C
    • Early Menopause and Response to HCV Treatment
  • Hepatitis C in Pregnancy
  • Treating Hepatitis C In Children
    • 2012 Hepatitis C infection in children
    • Autoimmunity/Extrahepatic Manifestations in HCV Treatment-Naïve Children
    • Study-long-term safety/durability of virologic response in paediatric patients who were previously treated w-interferon alfa-2b plus ribavirin for 48 weeks
  • Liver Disease in Elderly Patients
  • Dental considerations in patients with liver disease
    • HCV: Dental management-Diagnosis of extrahepatic manifestations>
      • Dental problems delaying the initiation of interferon
  • Fibrosis
    • Is there a natural way to improve liver fibrosis ?
  • 2013 News/Fibrosis
    • News: Fibrosis
  • Cirrhosis
    • What Is Cirrhosis ?
    • Advanced Liver Disease: What Every HCV Treater Should Know
    • The Patient With Cirrhosis: Don't Miss This
    • Hey, I have a question about cirrhosis
    • Physical Findings Suggestive Of Cirrhosis/Photos
    • Staging Cirrhosis>
      • When the Spleen Gets Tough, the Varices Get Going
    • Management Cirrhosis: How Are We Doing?
    • Cirrhosis Regression
    • Cirrhosis ; Surgery in the Patient with Liver Disease
    • Hepatic Encephalopathy>
      • Varices
      • Ascites
      • Management of ascites
  • 2013 News/Cirrhosis
    • News: Cirrhosis>
      • GI Bleeds: Withholding Transfusions Boosts Survival
  • Liver Transplant
    • New HCV Drugs:Expected Risks-Challenges in Liver Transplant
    • Prevention of hepatitis C recurrence after liver transplantation>
      • Effects of Telaprevir on Cyclosporine and Tacrolimus Pharmacokinetics Make Utility in Post-OLT Setting Uncertain
      • HCV Treatment After Liver Transplant
      • Antivirals Ineffective Against HCV After LT
  • 2013 News/Transplant
    • Liver Transplant News
  • Hepatocellular Carcinoma
    • Audio:Liver Cancer
    • Radioembolisation (RE),Selective Internal Radiation Therapy (SIRT)
    • Diagnosis (markers) of early hepatocellular carcinoma
    • Intrahepatic cholangiocarcinoma
    • Treatment TheraSphere/HCC/primary liver cancer
    • Liver Cancer : Microwave Ablation (MWA)
    • Pain May Predict Liver Cancer Prognosis
    • What Is the Indication for Sorafenib in Hepatocellular Carcinoma?
    • Liver Cysts and Tumors"Two Totally Different Concepts"
    • Interactive map of cancer mortality risk worldwide
  • 2013 News/Liver Cancer
    • Liver Cancer News and Updates
    • Vitamin E may lower liver cancer risk
  • Guidelines Nonalcoholic Fatty Liver Disease (NAFLD)
    • Fatty Liver And HCV>
      • Touching some firm ground in the epidemiology of NASH
      • Ultrasound/Liver Biopsy
      • Fatty Liver and Treatment
      • Liver fibrosis/Fatty Liver
  • 2013-Coffee and Liver Disease
  • Liver Regeneration
  • Liver Health
    • Choline: Great for the Liver
    • Medications for sleep in liver disease
    • The odds of gallbladder disease in Hepatitis C Patients
    • HCV & Gallbladder Disease:
    • Enlarged Spleen
    • HCV And Cardiovascular Risk
  • Nutrition-Herbs-Vitamins
    • Vitamin D and Treatment
    • Liver Disease - The Mediterranean Diet
    • Diet: Cirrhosis>
      • Low-Salt Diet-A Must in Cirrhosis
      • Diet for Liver Disease Low Sodium and More
      • Vitamin B12 supplements may help treat hepatitis
      • Nutrition in end-stage liver disease
      • Cirrhosis; Vitamin K Deficiencies
      • Vitamin D Levels In Cirrhosis
      • Vitamin D could de-stress Liver Disease Treatments
      • Drugs And Cirrhosis
      • Cancer and Berries
  • 2013-Silymarin for HCV infection
  • Milk Thistle
    • 2012-Milk Thistle No Help in Tough Hepatitis C Cases
    • Silymarin-Milk Thistle for NAFLD
    • Milk thistle"- Silibinin in hepatitis C related liver transplantation
    • Milk Thistle is coming to America
    • Caution! Herbs and Nutritional Supplements
  • HCV Drugs: Financial Support
  • HCV Filing For Social Security
  • Hepatitis C: A Rational Call To Arms
    • Hepatitis C; A Forced Legacy
    • Outsourcing:Globalization of the pharmaceutical industry>
      • Inspirational
  • Hepatitis C Links / Best On The Web
    • Chat and Message Boards
  • Whose Website Is This ?
  • Feedback/Contact Us

Original Article
 
Hepatitis C infection: challenges in dental management and diagnosis of extrahepatic manifestations
 
Volume 1, Number 1, Jan/Mar - 2012  
Journal of Oral Diagnosis 2012; 1(1): 15 - 19
 
Cláudia Misue Kanno1,3,4; Alvimar Lima de Castro2,3,4; Marcelo Macedo Crivelini2,3,4
 
1. Post-doctorate Program, Araçatuba School of Dentistry, Paulista State University, Araçatuba, São Paulo, Brazil.
2. Department of Pathology and Clinical Propaedeutics, Araçatuba School of Dentistry, Paulista
State University, Araçatuba, São Paulo, Brazil.
3. PhD.
4.  DDS.
 
Corresponding authors: Cláudia Misue Kanno Araçatuba School of Dentistry. Universidade Estadual Paulista
Rua José Bonifácio,  1193 Araçatuba - SP - Brasil CEP: 16015-050Tel: 55 (18) 3636 2822 Fax: 55  (18) 3636 3332
E-mail: cmkanno@foa.unesp.br

 
ABSTRACT
 
Hepatitis C is associated with autoimmune diseases, hepatocellular carcinoma,and extrahepatic manifestations that, in conjunction, may seriously compromise the patient's quality of life. We herein describe a case of chronic hepatitis C
with oral manifestations and discuss some implications for diagnosis and treatment. A 63-year-old woman complaining of spontaneous bleeding of the oral mucosa presented with bilateral asymmetric ulcers surrounded by white papules
and striae on the buccal mucosa. Her medical history revealed leucopenia,  thrombocytopenia, and skin lesions associated with chronic hepatitis C. 

Propranolol and ranitidine had recently been prescribed. Lichen planus, lichenoid reaction, and erythema multiforme were considered in the differential diagnosis. Histopathological analysis revealed lymphocytic infiltrate in a lichenoid pattern. The lesions partially healed after 1 week and completely regressed after 6 months, despite the maintenance of all medications; no
recurrence was observed. The final diagnosis was oral lichen planus associated with hepatitis C. Chronic hepatitis C may present oral manifestations, which demand adjustments in dental treatment planning. Medication side effects may
interfere with the clinical presentation and course of the disease and should be accounted for in the differential diagnosis. The possibility of spontaneous  remission of oral lichen planus should always be considered, especially when putative etiological factors of a lichenoid lesion are withdrawn in an attempt to differentiate oral lichen planus from lichenoid lesions. This case emphasizes  the importance of recognizing the extrahepatic manifestations of hepatitis C as  a cause of increased morbidity.
 
Keywords: chronic hepatitis c, leucopenia, oral diagnosis, oral lichen planus, thrombocytopenia.
 
INTRODUCTION

There is growing concern in medical and dental practice about the morbidity associated with hepatitis C. Hepatitis C virus (HCV), which causes the infection, is an RNA virus whose incubation period is about 6-7 weeks. The virus is contracted chiefly via the parenteral route, through blood product infusion or intravenous drug use. However, 30-40% of the infected patients have no history of such procedures1. In these cases, the possibility of transmission during dental procedures, ear piercing, tattooing, acupuncture, and endoscopic biopsies should be considered1.

 Symptoms of acute and chronic infections are usually mild and nonspecific, which makes dating of the infection onset difficult. Chronic infection develops in about 75% of the cases1-3. About 20-50% of the patients with chronic infection develop cirrhosis, which may culminate in hepatic failure or hepatocellular carcinoma3. Chronic hepatitis C is also associated with several immunological disturbances including mixed cryoglobulinemia, membranoproliferative glomerulonephritis, non-Hodgkin lymphoma, Sjögren syndrome, porphyria cutaneous tarda, endocrine and neurological manifestations,  leukocytoclastic vasculitis, and lichen planus1-3. These extrahepatic  manifestations are associated with increased mortality4.

Oral lichen planus (OLP) is a chronic mucocutaneous disease with uncertain etiology; it is classified as reticular, plaque, atrophic, erosive, or bullous according to the clinical presentation5. Emotional stress, immunological disturbances, neurological dysfunctions, and viruses are possible etiological factors1,5. Recent studies have shown a correlation between OLP and HCV.

The accumulated knowledge about hepatitis C seems to be insufficient because the infection is quite recently characterized. Therefore, many aspects concerning the mechanisms of immunological disturbances and their consequences are still uncertain. Here, we describe a case of chronic hepatitis C with oral manifestations and discuss some implications for iagnosis and treatment.

CASE REPORT 

A 63-year-old woman complained of oral soreness associated with spontaneous bleeding during masticatory movements and tooth brushing. The symptoms had started 3 days previously. Bilateral irregular ulcers surrounded by white papules and striae with bleeding on minor trauma were observed on the buccal mucosa. On the right side, they extended asymmetrically to the pterygomandibular fold (Figure 1), and the lesions were smaller on the left side (Figure 2). The patient had occlusal amalgam restorations and posterior porcelain veneers in the mandibular teeth and a maxillary removable partial denture.


Picture

Figure 1. Right buccal mucosa showing an ulcer surrounded by white striae.


Picture
Figure 2. Left buccal mucosa showing an ulcer with spontaneous bleeding.
 
 
Chronic hepatitis C had been diagnosed 12 years earlier. The mode of transmission was unknown. Treatment with interferon and, later, ribavirin had been tried. Unfortunately, the side effects were so strong that the therapy had to be discontinued.

Dermatological vasculitis and hematological disturbances had been previously diagnosed as the extrahepatic manifestations of hepatitis C. Idiopathic chronic thrombocytopenia and leucopenia had developed some years after the diagnosis of hepatitis C. Bone marrow biopsy revealed normal values, indicating no medullary impairment affecting blood cell production.

Her medical history also included arterial hypertension, gastric discomfort, rheumatism, and allergy to cephalosporin, clindamycin, and rifocin. Propranolol therapy for hypertension had been initiated 1 month before the onset of the buccal lesions. Ranitidine had been simultaneously prescribed for gastric discomfort control.

A biopsy was performed with the presumptive diagnosis of OLP, drug-induced lichenoid lesion, or erythema multiforme. On this occasion, her platelet count was 52,000/mm3. Histopathological examination revealed chronically inflamed mucosa with some ulcerated areas or outlined by atrophic epithelia. A band-like distribution of lymphocytic inflammatory infiltrate was seen in the subjacent lamina propria, at times associated with basal keratinocyte destruction (Figure 3). The histological features were compatible with OLP or lichenoid lesions.

Picture

Figure 3. Epithelial displacement from chronically inflamed connective tissue showing subepithelial band-like lymphocytic infiltration (hematoxylin and eosin stain; magnification, ×100 [A] and ×200 [B]). 
 
The postoperative period was uneventful. Partial healing of the oral ulcers was observed after 1 week. After 6 months, the ulcers healed completely, without recurrence (Figure 4). The platelet count was 110.000/mm3 and other hematological parameters were within the normal limits. During the entire follow-up period, the systemic therapy was not modified, which led to the final  diagnosis of OLP associated with hepatitis C.

Picture

Figure 4. Right intraoral view after 6 months showing healed areaswithout recurrence of ulcers.

DISCUSSION

Some dental procedures can be life threatening for patients with HCV infection if the complications of chronic infection are not anticipated during treatment planning. In our case, the superimposition of several extrahepatic manifestations of chronic hepatitis C and the possibility of side effects of the instituted therapies made the final diagnosis of the oral lesions challenging.
Of special concern for dental management, the patient presented leucopenia, thrombocytopenia, and oral lesions.

Thrombocytopenia may occur due to increased destruction, diminished production, or abnormal distribution of platelets in blood5. In the present case, HCV infection may have triggered autoimmune destruction of platelets, as medullary impairment was absent. Treatment for thrombocytopenia is determined by the severity of symptoms. Corticosteroids or intravenous immunoglobins are administered as immunosuppressants in most cases6,7, but no therapy is required in mild conditions. In the present case, corticosteroid therapy was contraindicated because of chronic leucopenia. Splenectomy is indicated in
refractive and chronic conditions of spleen functional impairment8. Spleen removal is justified for its role in antibody production and platelet sequestration from blood9,10. However, the patient's hemostatic parameters were not stable for splenectomy to be performed. Therefore, thrombocytopenia was monitored through periodical hematological analysis.


*The combination of interferon with ribavirin is considered an effective treatment for hepatitis C and has improved survival rates. Unfortunately, the therapy effectiveness is still limited and is associated with important side effects. The adverse effects of interferon include neuropsychiatric problems, fever, chills, headache, fatigue, arthralgia, granulocytopenia, and thrombocytopenia3. Ribavirin is a teratogen and causes a decrease in hemoglobin. Therapy withdrawal due to complications is quite common. 

In the present case, interferon and ribavirin worsened the hematological parameters and had to be withdrawn.

 The epidemiological relationship between OLP and hepatitis C has been reported11,12, notably in the erosive type13,14 and asymmetric lesions on the buccal mucosa15. However, the prevalence of OLP associated with hepatitis C presents geographical variations. This association is well documented in Italy13,15, Japan16,17, and Thailand12. In Brazil, a high prevalence of OLP in patients with HCV infection was found in São Paulo11 but not in Rio de Janeiro18. There is no consensus to explain this intriguing fact. Genetic variation among the populations seems to be the main factor accounting for these  differences19. On the other 18 Journal of Oral Diagnosis 1 (1) January/March  2012 hand, the incidence of OLP as an extrahepatic manifestation is probably low in the early phase of the infection, and therefore, dating of HCV contraction
should be considered in the diagnosis.

RNA filaments of HCV have been detected in OLP, suggesting that the lesionrepresents an extrahepatic site of viral proliferation16,17,20,21. The well-known association of HCV with hepatocellular carcinoma raises the question whether the virus plays a role in malignant transformation of OLP. Although evidence of increased rates of malignant transformation of OLP associated with HCV infection is lacking, its possibility justifies a long-term follow-up of the cases.

The presumptive role of HCV in the pathogenesis of OLP is still unknown. It does not seem to cause OLP by itself, because the virus is also found in normal cutaneous tissue of HCV carriers17. The lympho-mononuclear infiltrate, which is one of the main histological features of OLP, strongly suggests that the progressive epithelial destruction is due to a local immune response11,19. 

Patients with hepatitis C and OLP present relatively high quantities of antibodies against oral mucosa antigens, which are not observed in uninfected patients with the lesion22. Therefore, a host immune response, rather than viral factors, seems to be a determinant for the occurrence of OLP11,23 as well as cytopenias associated with hepatitis C4. Interestingly, in the present case, besides the remission of the oral lesions, the platelet count reached 110.000/mm3 5 months after the initial appointment, without specific treatment. These facts suggest that immunological mechanisms can show variations not related to treatment, which could account for the patient's general health improvement. Nevertheless, clinical relapse elicited by any stress infectious, viral, deficiencies, or medicines) is expected.

OLP should always be differentiated from oral lichenoid lesions, which share clinical and histological features. Lichenoid lesions differ from OLP by having a known cause that may be either local, such as amalgam restorations, or systemic, usually drugs prescribed for several purposes. The diagnostic assessment consists of a comprehensive and detailed drug history investigation, emphasizing the type of medication and starting and finishing date of administration in correlation with the onset of the lesions24. The final diagnosis is established after the total withdrawal of all putative etiological factors of lichenoid lesions, because regression of the lesions is expected.
 
Unfortunately, the withdrawal of all medications is not always possible due to the systemic condition of the patient or complex relationship of diseases.

In our case, partial healing of the oral lesions was observed 1 week after the initial appointment, although the therapy was not modified. The fact excluded the hypothesis of oral lichenoid lesions induced by medications. If the putative etiological factors for lichenoid lesions had been withdrawn, the final diagnosis could be erroneously defined as lichenoid lesions. Apparently, lesion regression was associated with spontaneous alterations in the immune response and occurred independently of drug withdrawal. Therefore, the possibility of spontaneous remission of hepatitis C-associated OLP should be considered when
medicines are withdrawn to differentiate OLP from lichenoid lesions.

CONCLUSION

 In conclusion, hepatitis C may lead to several immunological disturbances that compromise life quality. In this respect, both the extrahepatic manifestations of the infection and the medication side effects should be considered in the diagnosis of oral lesions and dental treatment planning. The possibility of spontaneous remission of OLP should always be considered,
especially when the putative etiological factors of lichenoid lesions are withdrawn to differentiate OLP from lichenoid lesions.

REFERENCES

 1. Pawlotsky JM, Dhumeaux D, Bagot M. Hepatitis C vírus in dermatology: a
review. Arch Dermatol. 1995;131(10):1185-93.

2. Gumber SC, Chopra S. Hepatitis C: a multifaceted disease. Review of
extrahepatic manifestations. Ann Intern Med. 1995;123(8):615-20.

3. Bonkovsky HL, Mehta S. Hepatitis C: a review and update. J Am Acad
Dermatol. 2001;44:159-79.

4. Vassilopoulos D, Calabrese LH. Extrahepatic immunological complications of
hepatitis C virus infection. AIDS. 2005;19 Suppl 3:S123-7.

 5. Sonis ST, Fazio RC, Fang L. Principles and practice of oral medicine. 2nd
ed. Philadelphia: WB Sounders; 1995. p. 242-61.

6. Bouroncle BA, Doan CA. Treatment of refractory idiopathic thrombocytopenic
purpura. JAMA. 1969;207:2049.

7. Laros RK, Penner JA. Refractory thrombocytopenic purpura treated
successfully with cyclophosphamide. JAMA. 1971;215(3):445.

8. Yeager DA. Idiopathic thrombocytopenic purpura: report of case. JADA.
1975;90(3):640-3.

9. Syracuse EP. Purpura - a review. J Oral Med. 1975;30(1):21-3.
 
10. Fotos PG, Graham WL, Bowers DC, Perfetto SP. Chronic autoimmune
thrombocytopenic purpura. A 3-year case study. Oral Surg Oral Med Oral Pathol.
1983;55(6):564-7.

 11. Figueiredo LC, Carrilho FJ, de Andrage HF, Migliari DA. Oral lichen
planus and hepatitis C virus infection. Oral Dis. 2002;8(1):42-6.

12. Klanrit P, Thongprasom K, Rojanawatsirivej S, Theamboonlers A, Poovorawan
Y. Hepatitis C virus infection in Thai patients with oral lichen planus. Oral
Dis. 2003;9(6):292-7.

13. Gandolfo S, Carbone M, Carrozzo M, Gallo V. Oral lichen planus and
hepatitis C vírus (HCV) infection: is there a relationship? A report of 10
cases. J Oral Pathol Med. 1994;23(3):119-22.

14. Carrozo M, Gandolfo S, Carbone M, Colombatto P, Broccoletti R,
Garzino-Demo P, et al. Hepatitis C vírus infection in Italian patients with oral
lichen planus: a prospective case-control study. J Oral Pathol Med.
1996;25(10):527-33.

15. Gimenez-Garcia R, Peres-Castrillón JL. Lichen planus and hepatitis C
virus infection. J Europ Acad Dermatol Venereol. 2003;17(3):291-5.

16. Nagao Y, Sata M. Hepatitis C virus and lichen planus. J Gastroenterol
Hepatol. 2004;19:1101-13.

17. ______., ______., Noguchi S, Seno'o T, Kinoshita M, Kameyama T, et al.
Detection of hepatitis C virus in oral lichen planus and oral cancer tissues. J
Oral Pathol Med. 2000;29(6):259-66.

18. Cunha KS, Manso AC, Cardoso AS, Paixao JB, Coelho HS, Torres SR.
Prevalence of oral lichen planus in Brazilian patients with HCV infection. Oral
Surg Oral Med Oral Pathol Oral Radiol Endod. 2005;100(3):330-3.

19. Lodi G, Scully C, Carrozzo M, Griffiths M, Sugerman PB, Thongprasom K.
Current controversies in oral lichen planus: report of an international
consensus meeting. Part 1. Viral infections and etiopathogenesis. Oral Surg Oral
Med Oral Pathol Oral Radiol Endod. 2005;100(1):40-51.

 20. Lazaro P, Olalquiaga J, Bartolomé J, Ortiz-Movilla N, Rodríguez-Iñigo E,
Pardo M, et al. Detection of hepatitis C virus RNA and core protein in
keratinocytes from patients with cutaneous lichen planus and chronic hepatitis
C. J Invest Dermatol. 2002;119(4):798-803.

21. Kurokawa M, Hidaka T, Sasaki H, Nishikata I, Morishita K, Setoyama M.
Analysis of hepatitis C virus (HCV) RNA in the lesions of lichen planus in
patients with chronic hepatitis C, detection of anti-genomic- as well as
genomic-strand HCV RNAs in lichen planus lesions. J Dermatol Sci.
2003;32(1):65-70.

22. Lodi G, Olsen I, Piattelli A, D'Amico E, Artese L, Portes SR. Antibodies
to epithelial components in oral lichen planus (OLP) associated with hepatitis C
virus (HCV) infection. J Oral Pathol Med. 1997;26(1):36-9.

23. Harden D, Skelton H, Smith KJ. Lichen planus associated with hepatitis C
virus: no viral transcripts are found in the lichen planus, and effective
therapy for hepatitis C virus does not clear lichen planus. J Am Acad Dermatol.
2003;49(5):847-52.

24. McCartan BE, McCreary CE, Heary CM. Studies of drug-induced lichenoid
lesion: Criteria for case selection. Oral Dis. 2003;9(4):163-4.

http://www.jordi.com.br/detalhe_artigo.asp?id=5

Copyright 2010-2013 Hepatitis C New Drug Research And Liver Health